Neuraly, Inc.

More mid-stage clinical trial failures are piling up in the Parkinson’s disease space, with the latest disappointment coming from South Korea's Bukwang Pharmaceutical Co., Ltd. , underlining the diff

The news this week that a GLP-1 agonist had succeeded in improving the symptoms of Parkinson’s disease was curious for two reasons: one, several trials of similar incretins in the condition have faile

AbbVie Inc. 's recent regulatory setback for a promising Parkinson's disease product has not skewed the US major's interest in the neurodegenerative disease, as the acquisition of Mitokinin, Inc. cl

Neuraly, Inc. ’s lead candidate, NLY01, has failed a Phase II trial in early Parkinson’s disease (PD) and while the firm touted a positive signal in under 60s, next steps for the program are unclear i